FDA Approves HIFU Clinical Trial For Recurrent Prostate Cancer
May 15th 2008Drug InformationProstate
USHIFU, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy. Dr.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
